Bruker to Seek Injunction, Appeal After Court Sides with 10x Genomics in Patent Dispute

Dow Jones2024-12-24
 

By Denny Jacob

 

Scientific instruments maker Bruker said it disagreed with a court ruling in a patent infringement case between its NanoString business and 10x Genomics.

Todd Garland, president of Bruker spatial biology division, said the company expects to promptly seek a stay of any injunction that is finally ordered in the case involving NanoString's GeoMx products.

"We also look forward to the appeal of our case being heard by the U.S. Court of Appeals for the Federal Circuit, a court that specializes in patent disputes," he added.

10x Genomics on Monday said the U.S. District Court for the District of Delaware ruled against the GeoMx products sold by Bruker.

The injunction, which the court said it will enter in January, is expected to prohibit Bruker from making, selling, using or offering to sell in the United States its GeoMx digital spatial profiler and associated instruments for RNA and protein detection, the company added. 10x Genomics also said the court affirmed the $31 million damages awarded by a jury in November 2023, as well as supplemented damages and interest that will be added to the total damages when the final judgment is entered.

The ruling follows the November 2023 jury verdict that found that NanoString's GeoMx products willfully infringed seven patents exclusively licensed to 10x Genomics by Prognosys.

 

Write to Denny Jacob at denny.jacob@wsj.com

 

(END) Dow Jones Newswires

December 24, 2024 10:19 ET (15:19 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment